Testing a new lung cancer drug for people with specific genetic mutations

This trial is testing a medication called zipalertinib to see if it can help people with advanced lung cancer that has specific genetic mutations. The study is enrolling about 220 people across multiple countries. Zipalertinib is a pill taken twice daily, and researchers want to understand how well it works and how safe it is for different groups of patients.

Some lung cancers have specific genetic changes that make them hard to treat with standard chemotherapy. This medication is designed to target these mutations directly, and researchers want to confirm it works and to find the best dose for different patient situations.